MADRIGAL PHARMACEUTICALS, INC. Sale of Stock, Consideration Received on Transaction
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Sale of Stock, Consideration Received on Transaction of $85.90 million for the 1-month period ending 2024-04-30, per its 10-Q filed 2024-10-31.
Financial Statements › Notes
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2024-10-31
- 2024-04-30: Sale of Stock, Consideration Received on Transaction 1 month $85.90M.
- 2024-03-31: Sale of Stock, Consideration Received on Transaction 1 month $574.00M.
| Period end | Sale of Stock, Consideration Received on Transaction 1 month |
|---|---|
| 2024-04-30 | $85.90M 10-Q · filed 2024-10-31 |
| 2024-03-31 | $574.00M 10-Q · filed 2024-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |